Add-on value of tirzepatide versus semaglutide.

Glycated Hemoglobin A; Hypoglycemic Agents; 53AXN4NNHX (semaglutide); Gastric Inhibitory Polypeptide; Glucagon-Like Peptides; OYN3CCI6QE (tirzepatide); Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptides/therapeutic use; Glycated Hemoglobin A/analysis; Humans; Hypoglycemic Agents/therapeutic use

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine,

Language :

English

Title :

Add-on value of tirzepatide versus semaglutide.

Publication date :

June 2022

Journal title :

The Lancet Diabetes and Endocrinology

ISSN :

2213-8587

eISSN :

2213-8595

Publisher :

Elsevier, Nl

Volume :

Issue :

Pages :

377-378

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 August 2022

Statistics

Number of views

49 (2 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Nauck, MA, Quast, DR, Wefers, J, Meier, JJ, GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab, 46, 2021, 101102.
Draznin, B, Aroda, VR, Bakris, G, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care 45:suppl 1 (2022), S125–S143.
Holst, JJ, Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 Banting medal for scientific achievement award lecture. Diabetes 70 (2021), 2468–2475.
Frías, JP, Davies, MJ, Rosenstock, J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385 (2021), 503–515.
Thomas, MK, Nikooienejad, A, Bray, R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 106 (2021), 388–396.
Heise, T, Mari, A, DeVries, HJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol, 2022 published online April 22. https://doi.org/10.1016/S2213-8587(22)00085-7.
Scheen, AJ, GLP-1 receptor agonists: which added value when increasing the dose?. Lancet Diabetes Endocrinol 9 (2021), 546–548.
El, K, Gray, SM, Capozzi, ME, et al. GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells. Sci Adv, 7, 2021, eabf1948.
Scheen, AJ, Van Gaal, LF, Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2 (2014), 911–922.
Samms, RJ, Christe, ME, Collins, KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest, 131, 2021, 146353.